167 related articles for article (PubMed ID: 9794505)
1. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats.
Hashimoto Y; Sasa H; Shimomura M; Inui K
Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505
[TBL] [Abstract][Full Text] [Related]
2. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus.
Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K
J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction.
Okabe H; Yano I; Hashimoto Y; Saito H; Inui K
J Pharm Pharmacol; 2002 Jan; 54(1):65-70. PubMed ID: 11829131
[TBL] [Abstract][Full Text] [Related]
4. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats.
Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
Drug Metab Pharmacokinet; 2008; 23(6):469-75. PubMed ID: 19122342
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.
Floren LC; Bekersky I; Benet LZ; Mekki Q; Dressler D; Lee JW; Roberts JP; Hebert MF
Clin Pharmacol Ther; 1997 Jul; 62(1):41-9. PubMed ID: 9246018
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic drug monitoring of immunosuppresants].
Hashida T; Inui K
Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
[TBL] [Abstract][Full Text] [Related]
7. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients.
Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513
[TBL] [Abstract][Full Text] [Related]
9. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy.
Shimada T; Terada A; Yokogawa K; Kaneko H; Nomura M; Kaji K; Kaneko S; Kobayashi K; Miyamoto K
Transplantation; 2002 Nov; 74(10):1419-24. PubMed ID: 12451243
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506).
Qin XL; Bi HC; Wang XD; Li JL; Wang Y; Xue XP; Chen X; Wang CX; Xu le J; Wang YT; Huang M
Int J Pharm; 2010 Apr; 389(1-2):114-21. PubMed ID: 20097278
[TBL] [Abstract][Full Text] [Related]
12. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.
Hebert MF; Fisher RM; Marsh CL; Dressler D; Bekersky I
J Clin Pharmacol; 1999 Jan; 39(1):91-6. PubMed ID: 9987705
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of lower maintenance dose of tacrolimus in obese patients.
Sawamoto K; Huong TT; Sugimoto N; Mizutani Y; Sai Y; Miyamoto K
Drug Metab Pharmacokinet; 2014; 29(4):341-7. PubMed ID: 24670405
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction.
Okabe H; Hashimoto Y; Inui KI
J Pharm Pharmacol; 2000 Dec; 52(12):1467-72. PubMed ID: 11197074
[TBL] [Abstract][Full Text] [Related]
15. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice.
Chiou WL; Chung SM; Wu TC
Pharm Res; 2000 Feb; 17(2):205-8. PubMed ID: 10751036
[TBL] [Abstract][Full Text] [Related]
16. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
[TBL] [Abstract][Full Text] [Related]
17. Hepatic extraction of tacrolimus in rats with experimental liver diseases.
Sasa H; Hashimoto Y; Shimizu T; Inui K
Biol Pharm Bull; 1998 Jun; 21(6):610-4. PubMed ID: 9657047
[TBL] [Abstract][Full Text] [Related]
18. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ
Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995
[TBL] [Abstract][Full Text] [Related]
19. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
20. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor].
Niwa T; Shiraga T; Omura M; Kondo T; Kuroda M; Takagi A
Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):395-404. PubMed ID: 17167213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
